Company BeyondSpring Inc.

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
1.8 ^USD	-2.70%		-12.62%	+100.00%

Apr. 15	North American Morning Briefing : Stock Futures -2-	DJ
Mar. 25	BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	MT

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Number of employees: 73

USD in Million	2021	Weight	2022	Weight	Delta
Targeted Protein Degradation Platform 100.0 %	-	-	1	100.0 %	-

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	0.00%

Managers	Title	Age	Since
Lan Huang CEO	Chief Executive Officer	53	12-12-31
G. Kenneth Lloyd CTO	Chief Tech/Sci/R&D Officer	80	15-05-31

Members of the board	Title	Age	Since
Patrick Fabbio BRD	Director/Board Member	56	18-01-01
Lan Huang CEO	Chief Executive Officer	53	12-12-31
Matthew Kirkby BRD	Director/Board Member	55	16-10-12
Yanbin Xie BRD	Director/Board Member	65	16-04-30
Brendan Delaney BRD	Director/Board Member	49	21-07-13
Jiang Wen Majeti BRD	Director/Board Member	56	22-07-31
Si Hai Xu BRD	Director/Board Member	52	22-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	39,015,476	28,620,321 ( 73.36 %)	0	73.36 %

Name	Equities	%	Valuation
Lan Huang 26.17 %	10,210,523	26.17 %	36 M $
Decheng Capital LLC 12.71 %	4,958,143	12.71 %	18 M $
BlackRock Institutional Trust Co. NA 0.5409 %	211,045	0.5409 %	753 431 $
Group One Trading LP 0.1461 %	56,986	0.1461 %	203 440 $
Jiang Wen Majeti 0.1305 %	50,914	0.1305 %	181 763 $
Capstone Capital LLC 0.1294 %	50,500	0.1294 %	180 285 $
G. Kenneth Lloyd 0.1042 %	40,641	0.1042 %	145 088 $
Acadian Asset Management LLC 0.0892 %	34,799	0.0892 %	124 232 $
STATE STREET CORPORATION 0.0825 %	32,200	0.0825 %	114 954 $
Tanaka Capital Management, Inc. 0.0755 %	29,473	0.0755 %	105 219 $

BeyondSpring, Inc.

28 Liberty Street 39th floor

10005, New York

http://www.beyondspringpharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BEYONDSPRING INC.	+101.11%	72.18M
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+1.77%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.29%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.88%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.91%	11.06B

Bio Therapeutic Drugs